Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation
Megadott ok: Institutional and funding constrains
A legfontosabb adatok
- Fázis
- 1/2. fázis
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálat adatai
- Ki végzi
- Sadat City University
- Azonosító
- NCT05453916
- A regiszteradat frissítve
- 2025. július 14.
- Eredeti leírás
This study aim to compare the efficacy of nitazoxanide in 2-week course of treatment with rifaximin in treating diarrhea associated with IBS. We also aim to study its effect over 10 weeks after treatment to evaluate its efficacy in eradicating symptoms of IBS in the long run.A teljes eredeti leírásKevesebb
A Randomized Single-Blind Controlled Trial Comparing the Efficacy of Nitazoxanide Versus Rifaximin in Adult Patients With Irritable Bowel Syndrome Without Constipation
This study aim to compare the efficacy of nitazoxanide in 2-week course of treatment with rifaximin in treating diarrhea associated with IBS. We also aim to study its effect over 10 weeks after treatment to evaluate its efficacy in eradicating symptoms of IBS in the long run.
Bevonási feltételek: Patients 18 years of age or older; Patients suffering from diarrhea-predominant IBS according to Rome III criteria; Active symptoms for at least 2 weeks; Abdominal Pain Intensity: weekly average of worst daily (in past 24 hours) abdominal pain score of > 3.0 on a 0-to-10-point scale and Stool Consistency: at least one stool with a consistency of Type 6 or Type 7 Bristol stool score (BSS) on at least 2 days per week; Report no restriction whatsoever on their diet.
Kizáró feltételek: Patients who consumed any medications that may affect bowel function within the last 2 weeks such as antibiotics, probiotics, prebiotics, antispasmodics, antidiarrheals, narcotics, or any other medication that may alter bowel function; Patients on antidepressants or antipsychotics starting within the last six weeks before eligibility check; Presence of liver disease, malignancy, severe malabsorption, bedridden, endocrinological disorders, or severe chronic obstructive pulmonary disease; Patients who have undergone abdominal surgeries except for appendectomy and/or cholecystectomy and/or hysterectomy.